Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1552 Trials   75151 News 


«12...7891011121314151617...858859»
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  A Quality Approach to Blinatumomab Delivery in Pediatric Oncology: A Children's Oncology Group Study. (Pubmed Central) -  Dec 1, 2024   
    Clinicians provided recommendations to assist others with blinatumomab administration and offered suggestions for items that could help with implementing future clinical trials containing similar agents. Findings suggest nurses are pivotal to establishing processes which support safe administration of immunotherapies, such as blinatumomab, while also considering patient-specific needs and promoting quality of life.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Pediatric Compounding Conundrums: Just Keep Swimming (MCCNO, Ballroom B, Level 2) -  Dec 1, 2024 - Abstract #ASHP2024ASHP_4928;    
    Using a choose your adventure format, this session will provide insight into some of the challenges for compounding pediatric patient formulations and highlight opportunities and challenges related to this type of compounding, including managing 12-hour beyond-use dates (BUDs) for stock solutions (a new requirement with USP updates), understanding the limits of IV automation and systems and their impact on compounding processes, managing dilutions of products with limited stability information, and determining the appropriate BUD for blinatumomab after recent package insert changes...Predict the impact of IV workflow and automatic limits on preparing pediatric doses. Assign beyond-use dates for products prepared from stock solutions.
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Journal:  USP7 deubiquitinates KRAS and promotes non-small cell lung cancer. (Pubmed Central) -  Nov 30, 2024   
    Moreover, USP7 inhibitors suppress NSCLC cell proliferation, particularly in cells resistant to the KRAS-G12C inhibitor AMG510. In conclusion, our findings identify USP7 as a key deubiquitinase regulating RAS stability, and targeting USP7 is a promising strategy to counteract KRAS inhibitor resistance in NSCLC.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Medical Management for Fracture Prevention in Children with Osteogenesis Imperfecta. (Pubmed Central) -  Nov 29, 2024   
    New therapies are undergoing clinical trials, and it is likely that one or more will receive marketing authorisation within the next three to five years. The long-term outcome from such interventions will need to be studied carefully well beyond the period over which the clinical trials are conducted, and a consistent approach to the collection of data in this regard will be needed as a major collaborative effort.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Review, Journal, Real-world evidence, Real-world:  Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes. (Pubmed Central) -  Nov 29, 2024   
    Herein, we discuss strategies to address the unique adverse effects of blinatumomab and ways to optimize its administration and integration into the treatment backbone of B-ALL. We outline our approach to combining and sequencing blinatumomab with other immunotherapies, such as INO and CD19 CAR T-cells, and provide recommendations for the management of toxicities and dose-optimization of blinatumomab therapy in clinical practice.
  • ||||||||||  Calsed (amrubicin) / BMS, Nippon Kayaku, Mycamine (micafungin) / Astellas, Neulasta (pegfilgrastim) / Roche
    Journal:  Candida Epiglottitis in a Patient Undergoing Chemotherapy for Small Cell Lung Cancer: A Case Report. (Pubmed Central) -  Nov 29, 2024   
    On the 10th day after receiving amrubicin and pegfilgrastim, he developed fever and a sore throat, presenting to the clinic the following day...The patient was hospitalized and treated with intravenous micafungin and meropenem, along with amphotericin B gargles...Antifungal therapy was completed within 11 days of hospitalization. This case underscores the importance of considering Candida epiglottitis in immunocompromised patients presenting with a sore throat, as prompt diagnosis and treatment are essential to prevent potentially fatal complications.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Denosumab and risk of hypocalcaemia  (Pubmed Central) -  Nov 29, 2024   
    This case underscores the importance of considering Candida epiglottitis in immunocompromised patients presenting with a sore throat, as prompt diagnosis and treatment are essential to prevent potentially fatal complications. No abstract available
  • ||||||||||  Tavneos (avacopan) / Amgen
    Journal:  C5aR expression in kidney tubules, macrophages and fibrosis. (Pubmed Central) -  Nov 28, 2024   
    C5a activity was C5aR dependent, as demonstrated by reversal with the C5aR inhibitor avacopan. Collectively, these results suggest that myeloid C5aR may induce excessive inflammation in the kidney via immune cell recruitment, extracellular matrix destruction, and remodeling, resulting in fibrotic tissue deposition.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Preclinical, Journal:  EGFR bypass activation mediates acquired resistance to regorafenib in hepatocellular carcinoma. (Pubmed Central) -  Nov 28, 2024   
    Inhibition of EGFR restores sensitivity to regorafenib, and the combination of gefitinib and regorafenib demonstrates significant antitumor efficacy both in vivo and in vitro. These findings suggest that this combination could be a potential strategy for patients with advanced HCC.
  • ||||||||||  Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
    Retrospective data, Journal:  Therapy with transitions from one bone-forming agent to another: a retrospective cohort study on teriparatide and romosozumab. (Pubmed Central) -  Nov 28, 2024   
    Furthermore, when examining the changes in the proportion of patients who achieved the osteoporosis treatment goal of a T-score exceeding -2.5, no significant increase was observed in the R2T group, whereas a significant increase was observed in the lumbar spine in the T2R group. Regarding therapy switching between bone-forming agents, this study suggests that transitioning from teriparatide to romosozumab increases BMD more effectively than transitioning in the opposite sequence.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, UNC1999 - University of North Carolina / Chapel Hill
    Journal:  Ezh2 Delays Activation of Differentiation Genes During Normal Cerebellar Granule Neuron Development and in Medulloblastoma. (Pubmed Central) -  Nov 28, 2024   
    Similarly, in MB cells, neuronal differentiation could be induced by preventing H3K27me3 modifications using an Ezh2 inhibitor (UNC1999), but only when UNC1999 was combined with forced cell cycle exit driven by a CDK4/6 inhibitor (Palbociclib). Ezh2 emerges as a powerful restraint upon post-mitotic differentiation during normal GNP development and combination of Ezh2 inhibition with cell cycle exit leads to MB cell differentiation.
  • ||||||||||  Lumakras (sotorasib) / Amgen
    Journal:  FGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in KRAS G12C Lung Cancer. (Pubmed Central) -  Nov 28, 2024   
    Importantly, treatment of mice with FGTI-2734 inhibited sotorasib-induced ERK reactivation in KRAS G12C PDX, and treatment of mice with the combination of FGTI-2734 and sotorasib were also significantly more effective at suppressing in vivo the levels of P-ERK in sotorasib-resistant human KRAS G12C lung cancer xenografts as well as a PDX. Our findings provide a foundation for overcoming sotorasib resistance and potentially improving the treatment outcomes of KRAS G12C lung cancer.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Journal:  Injectable Polydopamine Nanoparticle-Incorporated Hydrogels for Antiangiogenesis and Stimulating Tumoricidal Immunity to Inhibit Metastasis and Recurrence Postresection. (Pubmed Central) -  Nov 28, 2024   
    This nanoregulator together with regorafenib (REG) was further incorporated into a hydrogel developed from grafting adipic acid dihydrazide onto 2,2,6,6-tetramethylpiperidine-1-oxyl radical oxidized chitin and oxidized hyaluronic acid, which was injectable at the cavity after subcutaneous tumor surgery with good mechanical properties and degradability...This effect was achieved by suppressing angiogenesis and enhancing antitumor immunity, characterized by increased levels of effector T lymphocytes and activation of dendritic cells within tumors, spleens, and draining lymph nodes. The injectable hydrogel offers a promising strategy for postoperative management aimed at preventing tumor metastasis and recurrence.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Review, Journal:  Palbociclib as an Antitumor Drug: A License to Kill. (Pubmed Central) -  Nov 27, 2024   
    It discusses the therapeutic applications in breast cancer as well as in solid tumors and hematopoietic malignancies. Additionally, the paper presents an analysis of palbociclib resistance acquired during therapy and explores new approaches, such as modifications to palbociclib that enhance its desired activity or open up new therapeutic possibilities (PROTACs).
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Verzenio (abemaciclib) / Eli Lilly
    Review, Journal:  Cyclin-Dependent Kinase Inhibitors in the Rare Subtypes of Melanoma Therapy. (Pubmed Central) -  Nov 27, 2024   
    Herein, we discuss the past and current research relevant to targeting various CDKs in mucosal, uveal and acral melanomas. We also briefly describe the issue of amelanotic and desmoplastic types of melanoma and the need to do more research to discover cell cycle dysregulations, which cause the growth of the mentioned forms of cancer.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    PK/PD data, Preclinical, Journal:  A Pharmacokinetic Study of the Interaction Between Regorafenib and Paracetamol in Male Rats. (Pubmed Central) -  Nov 27, 2024   
    In contrast, REG reduced paracetamol exposure and contributed to its faster elimination, which may reduce the analgesic and antipyretic effects of paracetamol. These findings suggest clinical relevance for oncology patients requiring analgesic treatment.
  • ||||||||||  Review, Journal:  Therapies for Chronic Spontaneous Urticaria: Present and Future Developments. (Pubmed Central) -  Nov 27, 2024   
    Additionally, molecules targeting the Mas-related G protein-coupled receptor X2 (MRGPRX2), and those inhibiting the tyrosine kinase receptor Kit, such as barzolvolimab, show promise in clinical studies...Further research is essential to better elucidate the pathophysiology of CSU and optimize treatment protocols to achieve long-term benefits in managing this condition. Altogether, the future of CSU treatments that target pathogenetic mechanisms seems promising.
  • ||||||||||  Tavneos (avacopan) / Amgen
    Review, Journal:  Role of Avacopan on Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis. (Pubmed Central) -  Nov 27, 2024   
    Avacopan, a novel C5a receptor inhibitor, represents a promising therapeutic option for vasculitis with renal involvement. This article provides a comprehensive review of the role of complement in the pathogenesis of vasculitis with renal involvement and the role of avacopan for its treatment, taking into account recent updates to both the EULAR and KDIGO guidelines and published experience of avacopan use in real clinical settings.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Osteoporosis in Systemic Mastocytosis: A Scoping Review. (Pubmed Central) -  Nov 27, 2024   
    Studies have demonstrated the effectiveness of various treatments depending on the form of mastocytosis, whether indolent systemic or advanced systemic, in the prognosis of the disease. However, this role should be further investigated in additional clinical studies, considering the limited data on the use of these interventions.